Enzo Biochem, Inc. (NYSE:ENZ) saw a large growth in short interest in the month of March. As of March 29th, there was short interest totalling 1,091,233 shares, a growth of 42.7% from the March 15th total of 764,561 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 307,201 shares, the short-interest ratio is presently 3.6 days.

A number of hedge funds have recently modified their holdings of ENZ. Prudential Financial Inc. purchased a new stake in shares of Enzo Biochem during the 4th quarter worth $33,000. Sontag Advisory LLC purchased a new stake in shares of Enzo Biochem during the 4th quarter worth $43,000. Paradigm Financial Partners LLC purchased a new stake in shares of Enzo Biochem during the 4th quarter worth $48,000. Mraz Amerine & Associates Inc. purchased a new stake in shares of Enzo Biochem during the 4th quarter worth $50,000. Finally, Rhumbline Advisers lifted its position in shares of Enzo Biochem by 46.4% during the 4th quarter. Rhumbline Advisers now owns 60,542 shares of the medical research company’s stock worth $168,000 after purchasing an additional 19,181 shares during the last quarter. 67.28% of the stock is owned by institutional investors.

Shares of ENZ stock opened at $3.58 on Friday. The company has a current ratio of 3.83, a quick ratio of 3.38 and a debt-to-equity ratio of 0.07. Enzo Biochem has a 52 week low of $2.32 and a 52 week high of $6.89.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Monday, March 11th. The medical research company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). Enzo Biochem had a negative net margin of 25.55% and a negative return on equity of 29.83%. The business had revenue of $19.33 million during the quarter.

ILLEGAL ACTIVITY WARNING: “Enzo Biochem, Inc. (ENZ) Sees Significant Growth in Short Interest” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2019/04/18/enzo-biochem-inc-enz-sees-significant-growth-in-short-interest.html.

About Enzo Biochem

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Further Reading: Trading Strategy

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.